{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:29:48Z","timestamp":1792178988242,"version":"4.4.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T00:00:00Z","timestamp":1720396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13555-024-01220-1","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T11:01:50Z","timestamp":1720436510000},"page":"2127-2138","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development of the Cutaneous Dermatomyositis Investigator Global Assessment (CDM-IGA): A De Novo IGA of Cutaneous Manifestations of Dermatomyositis"],"prefix":"10.1007","volume":"14","author":[{"given":"Stephanie","family":"McKee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Xenakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet","family":"Makin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Marshall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall","family":"Winnette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Knight","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,8]]},"reference":[{"issue":"3","key":"1220_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40257-020-00502-6","volume":"21","author":"GA Cobos","year":"2020","unstructured":"Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020;21(3):339\u201353.","journal-title":"Am J Clin Dermatol"},{"issue":"5","key":"1220_CR2","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1080\/09546634.2017.1403549","volume":"29","author":"V Isak","year":"2018","unstructured":"Isak V, Jorizzo JL. Recent developments on treatment strategies and the prognosis of dermatomyositis: a review. J Dermatolog Treat. 2018;29(5):450\u20139.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"1220_CR3","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jocd.15363","volume":"22","author":"A Patil","year":"2023","unstructured":"Patil A, Lu J, Kassir M, Babaei M, Goldust M. Adult and juvenile dermatomyositis treatment. J Cosmet Dermatol. 2023;22(2):395\u2013401.","journal-title":"J Cosmet Dermatol"},{"key":"1220_CR4","unstructured":"Mayo Clinic. Dermatomyositis. https:\/\/www.mayoclinic.org\/diseases-conditions\/dermatomyositis\/symptoms-causes\/syc-20353188 Accessed Jun 2023."},{"key":"1220_CR5","unstructured":"National Organization for Rare Disorders. Dermatomyositis. https:\/\/rarediseases.org\/rare-diseases\/dermatomyositis\/ Accessed Jun 2023."},{"issue":"6","key":"1220_CR6","first-page":"409","volume":"65","author":"T Hu","year":"2019","unstructured":"Hu T, Vinik O. Dermatomyositis and malignancy. Can Fam Physician. 2019;65(6):409\u201311.","journal-title":"Can Fam Physician"},{"issue":"2","key":"1220_CR7","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40257-015-0120-1","volume":"16","author":"JM Olazagasti","year":"2015","unstructured":"Olazagasti JM, Baez PJ, Wetter DA, Ernste FC. Cancer risk in dermatomyositis: a meta-analysis of cohort studies. Am J Clin Dermatol. 2015;16(2):89\u201398.","journal-title":"Am J Clin Dermatol"},{"issue":"12","key":"1220_CR8","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.7326\/0003-4819-134-12-200106190-00008","volume":"134","author":"R Buchbinder","year":"2001","unstructured":"Buchbinder R, Forbes A, Hall S, Dennett X, Giles G. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med. 2001;134(12):1087\u201395.","journal-title":"Ann Intern Med"},{"key":"1220_CR9","doi-asserted-by":"publisher","first-page":"117954761985537","DOI":"10.1177\/1179547619855370","volume":"12","author":"J Okogbaa","year":"2019","unstructured":"Okogbaa J, Batiste L. Dermatomyositis: an acute flare and current treatments. Clin Med Insights Case Rep. 2019;12:1179547619855370.","journal-title":"Clin Med Insights Case Rep"},{"issue":"1","key":"1220_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-019-0332-7","volume":"17","author":"P Livermore","year":"2019","unstructured":"Livermore P, Gray S, Mulligan K, Stinson JN, Wedderburn LR, Gibson F. Being on the juvenile dermatomyositis rollercoaster: a qualitative study. Pediatr Rheumatol. 2019;17(1):1\u20139.","journal-title":"Pediatr Rheumatol"},{"issue":"3","key":"1220_CR11","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1080\/14728214.2020.1787985","volume":"25","author":"T Chandra","year":"2020","unstructured":"Chandra T, Aggarwal R. Clinical trials and novel therapeutics in dermatomyositis. Expert Opin Emerg Drugs. 2020;25(3):213\u201328.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"4","key":"1220_CR12","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.clindermatol.2018.04.003","volume":"36","author":"I Bogdanov","year":"2018","unstructured":"Bogdanov I, Kazandjieva J, Darlenski R, Tsankov N. Dermatomyositis: current concepts. Clin Dermatol. 2018;36(4):450\u20138.","journal-title":"Clin Dermatol"},{"issue":"11","key":"1220_CR13","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/rheumatology\/40.11.1262","volume":"40","author":"FW Miller","year":"2001","unstructured":"Miller FW, Rider LG, Chung YL, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology. 2001;40(11):1262\u201373.","journal-title":"Rheumatology"},{"issue":"Suppl 11","key":"1220_CR14","first-page":"S118","volume":"63","author":"LG Rider","year":"2011","unstructured":"Rider LG, Werth VP, Huber AM, et al. Measures of adult and juvenile dermatomyositis, polymyositis, and inclusion body myositis: Physician and Patient\/Parent Global Activity, Manual Muscle Testing (MMT), Health Assessment Questionnaire (HAQ)\/Childhood Health Assessment Questionnaire (C-HAQ), Childhood Myositis Assessment Scale (CMAS), Myositis Disease Activity Assessment Tool (MDAAT), Disease Activity Score (DAS), Short Form 36 (SF-36), Child Health Questionnaire (CHQ), physician global damage, Myositis Damage Index (MDI), Quantitative Muscle Testing (QMT), Myositis Functional Index-2 (FI-2), Myositis Activities Profile (MAP), Inclusion Body Myositis Functional Rating Scale (IBMFRS), Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI), Cutaneous Assessment Tool (CAT), Dermatomyositis Skin Severity Index (DSSI), Skindex, and Dermatology Life Quality Index (DLQI). Arthritis Care Res (Hoboken). 2011;63(Suppl 11):S118\u201357.","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"1220_CR15","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1038\/nrrheum.2018.33","volume":"14","author":"LG Rider","year":"2018","unstructured":"Rider LG, Aggarwal R, Machado PM, et al. Update on outcome assessment in myositis. Nat Rev Rheumatol. 2018;14(5):303\u201318.","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"1220_CR16","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1136\/annrheumdis-2017-211400","volume":"76","author":"R Aggarwal","year":"2017","unstructured":"Aggarwal R, Rider LG, Ruperto N, et al. 2016 American College of Rheumatology\/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group\/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis. 2017;76(5):792\u2013801.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"1220_CR17","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/bjd.13915","volume":"173","author":"CO Anyanwu","year":"2015","unstructured":"Anyanwu CO, Fiorentino DF, Chung L, et al. Validation of the cutaneous dermatomyositis disease area and severity index: characterizing disease severity and assessing responsiveness to clinical change. Br J Dermatol. 2015;173(4):969\u201374.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1220_CR18","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1111\/bjd.15140","volume":"176","author":"J Tiao","year":"2017","unstructured":"Tiao J, Feng R, Bird S, et al. The reliability of the cutaneous dermatomyositis disease area and severity index (CDASI) among dermatologists, rheumatologists and neurologists. Br J Dermatol. 2017;176(2):423\u201330.","journal-title":"Br J Dermatol"},{"key":"1220_CR19","volume-title":"Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims","author":"Food and Drug Administration (FDA)","year":"2009","unstructured":"Food and Drug Administration (FDA). Guidance for industry patient-reported outcome measures: use in medical product development to support labeling claims. FDA; 2009."},{"key":"1220_CR20","volume-title":"Patient-focused drug development: collecting comprehensive and representative input. Guidance for industry, Food and Drug Administration staff, and other stakeholders","author":"Food and Drug Administration (FDA)","year":"2020","unstructured":"Food and Drug Administration (FDA). Patient-focused drug development: collecting comprehensive and representative input. Guidance for industry, Food and Drug Administration staff, and other stakeholders. FDA; 2020."},{"key":"1220_CR21","volume-title":"Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. Guidance for industry (DRAFT), Food and Drug Administration staff, and other stakeholders","author":"Food and Drug Administration (FDA)","year":"2022","unstructured":"Food and Drug Administration (FDA). Patient-focused drug development: selecting, developing, or modifying fit-for-purpose clinical outcome assessments. Guidance for industry (DRAFT), Food and Drug Administration staff, and other stakeholders. FDA; 2022."},{"key":"1220_CR22","volume-title":"Patient-focused drug development: methods to identify what is important to patients. Guidance for industry, Food and Drug Administration staff, and other stakeholders","author":"Food and Drug Administration (FDA)","year":"2022","unstructured":"Food and Drug Administration (FDA). Patient-focused drug development: methods to identify what is important to patients. Guidance for industry, Food and Drug Administration staff, and other stakeholders. FDA; 2022."},{"key":"1220_CR23","volume-title":"Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making. Guidance for industry (DRAFT)","author":"Food and Drug Administration (FDA)","year":"2023","unstructured":"Food and Drug Administration (FDA). Patient-focused drug development: incorporating clinical outcome assessments into endpoints for regulatory decision-making. Guidance for industry (DRAFT). FDA; 2023."},{"key":"1220_CR24","volume-title":"Patient-focused drug development: select, develop or modify fit-for-purpose clinical outcome assessments. Guidance 3 discussion document","author":"Food and Drug Administration (FDA)","year":"2018","unstructured":"Food and Drug Administration (FDA). Patient-focused drug development: select, develop or modify fit-for-purpose clinical outcome assessments. Guidance 3 discussion document. FDA; 2018."},{"key":"1220_CR25","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s11747-011-0300-3","volume":"40","author":"D Adamantios","year":"2012","unstructured":"Adamantios D. Guidelines for choosing between multi-item and single-item scales for construct measurement: a predictive validity perspective. J Acad Mark Sci. 2012;40:434\u201349.","journal-title":"J Acad Mark Sci"},{"key":"1220_CR26","unstructured":"Acne Vulgaris: Establishing Effectiveness of Drugs Intended for Treatment Guidance for Industry. Food and Drug Administration, Center for Drug Evaluation and Research (CDER). 2018. Available from: https:\/\/www.fda.gov\/media\/71152\/download."},{"issue":"3","key":"1220_CR27","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s40257-019-00496-w","volume":"21","author":"LM Perez-Chada","year":"2020","unstructured":"Perez-Chada LM, Salame NF, Ford AR, et al. Investigator and patient global assessment measures for psoriasis clinical trials: a systematic review on measurement properties from the International Dermatology Outcome Measures (IDEOM) initiative. Am J Clin Dermatol. 2020;21(3):323\u201338.","journal-title":"Am J Clin Dermatol"},{"issue":"1","key":"1220_CR28","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3109\/09546634.2013.865009","volume":"26","author":"RG Langley","year":"2015","unstructured":"Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point investigator\u2019s global assessment (IGA) scale: a modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015;26(1):23\u201331.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"1220_CR29","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000023677","volume":"100","author":"R Aggarwal","year":"2021","unstructured":"Aggarwal R, Charles-Schoeman C, Schessl J, Dimachkie MM, Beckmann I, Levine T. Prospective, double-blind, randomized, placebo-controlled phase\u00a0III study evaluating efficacy and safety of octagam 10% in patients with dermatomyositis (\u201cProDERM study\u201d). Medicine (Baltimore). 2021;100(1):e23677.","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"1220_CR30","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1016\/j.jid.2022.03.029","volume":"142","author":"VP Werth","year":"2022","unstructured":"Werth VP, Hejazi E, Pena SM, et al. Safety and efficacy of lenabasum, a cannabinoid receptor type\u00a02 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial. J Invest Dermatol. 2022;142(10):2651-9.e1.","journal-title":"J Invest Dermatol"},{"key":"1220_CR31","unstructured":"Jensen E, Jones N, Rabe M, et al. The chance that two people chosen at random are of different race or ethnicity groups has increased since 2010. United States Census Bureau. 2021."}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01220-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01220-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01220-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T14:28:21Z","timestamp":1724077701000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01220-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,8]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1220"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01220-1","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,8]]},"assertion":[{"value":"14 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Jason Xenakis is a paid employee of Pfizer Inc. US. Sarah Knight, Stephanie McKee, Harriet Makin and Chris Marshall are paid employees of Clarivate. Randall Winnette is a current employee of Novartis. This research was conducted when Randall Winnette was an employee at Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Ethical review of the patient interview part of this study was sought from the WCG Independent Review Board (IRB) in the USA (approval date 8\u00a0September 2021, IRB tracking number 20214484, study number 1316795). This study was in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}